Epothilones in the treatment of cancer

Bibliography

• GERTH K, BEDORF N, HOFLE G, IRSCHIK H, REICHENBACH H: Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J. Antibiot. (Tokyo) (1996) 49(6):560-563.
   PubMed Web of Science ®Google Scholar
• BOLLAG DM, McQUENEY PA, ZHU J et al.: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. (1995) 55(11):2325-2333.
   PubMed Web of Science ®Google Scholar
• JORDAN MA, WILSON L: Microtubules as a target for anticancer drugs. Nat. Rev. Cancer (2004) 4(4):253-265.
   PubMed Web of Science ®Google Scholar
• VERDIER-PINARD P, WANG F, BURD B et al.: Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry. Biochemistry (2003) 42(41):12019-12027.
   PubMed Web of Science ®Google Scholar
• LUDUENA RF: Multiple forms of tubulin: different gene products and covalent modifications. Int. Rev. Cytol. (1998) 178:207-275.
   PubMed Web of Science ®Google Scholar
• GIODINI A, KALLIO MJ, WALL NR et al.: Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. (2002) 62(9):2462-2467.
   PubMed Web of Science ®Google Scholar
• GALMARINI CM, KAMATH K, VANIER-VIORNERY A et al.: Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br. J. Cancer (2003) 88(11):1793-1799.
   PubMed Web of Science ®Google Scholar
• MANEY T, WAGENBACH M, WORDEMAN L: Molecular dissection of the microtubule depolymerizing activity of mitotic centromere-associated kinesin. J. Biol. Chem. (2001) 276(37):34753-34758.
   PubMed Web of Science ®Google Scholar
• MARTELLO LA, VERDIER-PINARD P, SHEN HJ et al.: Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an α-tubulin mutation. Cancer Res. (2003) 63(6):1207-1213.
   PubMed Web of Science ®Google Scholar
• DUMONTET C, SIKIC BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. (1999) 17(3):1061-1070.
   PubMed Web of Science ®Google Scholar
• KAVALLARIS M, TAIT AS, WALSH BJ et al.: Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells. Cancer Res. (2001) 61(15):5803-5809.
   PubMed Web of Science ®Google Scholar
• COONEY MM, RADIVOYEVITCH T, DOWLATI A et al.: Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose Phase I study in patients with advanced cancer. Clin. Cancer Res. (2004) 10(1 Part 1):96-100.
   PubMed Web of Science ®Google Scholar
• ANDERSON HL, YAP JT, MILLER MP et al.: Assessment of pharmacodynamic vascular response in a Phase I trial of combretastatin A4 phosphate. J. Clin. Oncol. (2003) 21(15):2823-2830.
   PubMed Web of Science ®Google Scholar
• DOWLATI A, ROBERTSON K, COONEY M et al.: A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. (2002) 62(12):3408-3416.
   PubMed Web of Science ®Google Scholar
• RUSTIN GJ, GALBRAITH SM, ANDERSON H et al.: Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. (2003) 21(15):2815-2822.
   PubMed Web of Science ®Google Scholar
• STEVENSON JP, ROSEN M, SUN W et al.: Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. (2003) 21(23):4428-4438.
   PubMed Web of Science ®Google Scholar
• THORPE PE: Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. (2004) 10(2):415-427.
   PubMed Web of Science ®Google Scholar
• STEVENSON JP, SUN W, GALLAGHER M et al.: Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. Clin. Cancer Res. (2002) 8(8):2524-2529.
   PubMed Web of Science ®Google Scholar
• EDELMAN MJ, GANDARA DR, HAUSNER P et al.: Phase II study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer (2003) 39(2):197-199.
   PubMed Web of Science ®Google Scholar
• SESSA C, WEIGANG-KOHLER K, PAGANI O et al.: Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule. Eur. J. Cancer (2002) 38(18):2388-2396.
   PubMed Web of Science ®Google Scholar
• SIMMONS TL, ANDRIANASOLO E, McPHAIL K, FLATT P, GERWICK WH: Marine natural products as anticancer drugs. Mol. Cancer Ther. (2005) 4(2):333-342.
   PubMed Web of Science ®Google Scholar
• SWEENEY C, LIU G, YIANNOUTSOS C et al.: A Phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin. Cancer Res. (2005) 11(18):6625-6633.
   PubMed Web of Science ®Google Scholar
• YEE KW, HAGEY A, VERSTOVSEK S et al.: Phase I study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. (2005) 11(18):6615-6624.
   PubMed Web of Science ®Google Scholar
• NOGALES E, WOLF SG, KHAN IA, LUDUENA RF, DOWNING KH: Structure of tubulin at 6.5 Å and location of the taxol-binding site. Nature (1995) 375(6530):424-427.
   PubMed Web of Science ®Google Scholar
• JORDAN MA, WENDELL K, GARDINER S et al.: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. (1996) 56(4):816-825.
   PubMed Web of Science ®Google Scholar
• CHOU TC, ZHANG XG, BALOG A et al.: Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc. Natl. Acad. Sci. USA (1998) 95(16):9642-9647.
   PubMed Web of Science ®Google Scholar
• LEE FY, BORZILLERI R, FAIRCHILD CR et al.: BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. (2001) 7(5):1429-1437.
   PubMed Web of Science ®Google Scholar
• NEWMAN RA, YANG J, RAYMOND M et al.: Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother. Pharmacol. (2001) 48(4):319-326.
   PubMed Web of Science ®Google Scholar
• WARTMANN M, ALTMANN KH: The biology and medicinal chemistry of epothilones. Curr. Med. Chem. Anticancer Agents (2002) 2(1):123-148.
   PubMedGoogle Scholar
• CHOU TC, O’CONNOR OA, TONG WP et al.: The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc. Natl. Acad. Sci. USA (2001) 98(14):8113-8118.
   PubMed Web of Science ®Google Scholar
• BAIRD RD, KAYE SB: Drug resistance reversal-are we getting closer? Eur. J. Cancer (2003) 39(17):2450-2461.
   PubMed Web of Science ®Google Scholar
• BAEKELANDT MM, HOLM R, NESLAND JM, TROPE CG, KRISTENSEN GB: P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. (2000) 20(2B):1061-1067.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER J, JIMENEZ E, MARENBACH K, MARX D, MEDEN H: Co-expression of the MDR1 gene and HSP27 in human ovarian cancer. Anticancer Res. (1998) 18(4C):2967-2971.
   PubMed Web of Science ®Google Scholar
• PORUCHYNSKY MS, GIANNAKAKOU P, WARD Y et al.: Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem. Pharmacol. (2001) 62(11):1469-1480.
   PubMed Web of Science ®Google Scholar
• KOWALSKI RJ, GIANNAKAKOU P, HAMEL E: Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J. Biol. Chem. (1997) 272(4):2534-2541.
   PubMed Web of Science ®Google Scholar
• GIANNAKAKOU P, GUSSIO R, NOGALES E et al.: A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. USA (2000) 97(6):2904-2909.
   PubMed Web of Science ®Google Scholar
• VERRILLS NM, FLEMMING CL, LIU M et al.: Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug–target interactions. Chem. Biol. (2003) 10(7):597-607.
   PubMed Web of Science ®Google Scholar
• ALTMANN KH, WARTMANN M, O’REILLY T: Epothilones and related structures – a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim. Biophys. Acta (2000) 1470(3):M79-M91.
   PubMed Web of Science ®Google Scholar
• KAMATH AV, CHANG M, LEE FY, ZHANG Y, MARATHE PH: Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Cancer Chemother. Pharmacol. (2005) 56(2):145-153.
   PubMed Web of Science ®Google Scholar
• BLUM W, AICHHOLZ R, RAMSTEIN P et al.: In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry. Rapid Commun. Mass Spectrom. (2001) 15(1):41-49.
   PubMed Web of Science ®Google Scholar
• ABRAHAM J, AGRAWAL M, BAKKE S et al.: Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J. Clin. Oncol. (2003) 21(9):1866-1873.
   PubMed Web of Science ®Google Scholar
• GADGEEL SM, WOZNIAK A, BOINPALLY RR et al.: Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin. Cancer Res. (2005) 11(17):6233-6239.
   PubMed Web of Science ®Google Scholar
• MANI S, McDAID H, HAMILTON A et al.: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res. (2004) 10(4):1289-1298.
   PubMed Web of Science ®Google Scholar
• McDAID HM, MANI S, SHEN HJ et al.: Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a Phase I clinical study. Clin. Cancer Res. (2002) 8(7):2035-2043.
   PubMed Web of Science ®Google Scholar
• ZHUANG SH, AGRAWAL M, EDGERLY M et al.: A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer (2005) 103(9):1932-1938.
   PubMed Web of Science ®Google Scholar
• AWADA A, BLEIBERG H, DE VALERIOLA D et al.: Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients (Pts) with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 427).
   Web of Science ®Google Scholar
• BURRIS HA III, AWADA A, JONES S et al.: Phase I study of the novel epothilone BMS-247550 administered weekly in patients (pts) with advanced malignancies. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 412).
   Web of Science ®Google Scholar
• RUBIN EH, ROTHERMEL J, TESFAYE F et al.: Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J. Clin. Oncol. (2005) 23(36):9120-9129.
   PubMed Web of Science ®Google Scholar
• CALVERT PM, O’NEILL V, TWELVES C et al.: A Phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 429).
   Web of Science ®Google Scholar
• SPRIGGS DR, DUPONT J, PEZZULLI S et al.: KOS-862 (epothilone D): Phase I dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 894).
   Web of Science ®Google Scholar
• PIRO LD, ROSEN LS, PARSON M et al.: KOS-862 (epothilone D): a comparison of two schedules in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 539).
   Google Scholar
• HOLEN KD, SYED S, HANNAH AL et al.: Phase I study using continuous intravenous (CI) KOS-862 (epothilone D) in patients with solid tumors. J. Clin. Oncol. (2004) 23(14S):2024.
   Google Scholar
• MEKHAIL T, CHUNG C, HOLDEN S et al.: Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 515).
   Web of Science ®Google Scholar
• SESSA C, PEROTTI A, MALOSSI A et al.: Phase I and pharmacokinetic (PK) study of the novel epothilone BMS-310705 in patients (pts) with advanced solid cancer. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 519).
   Google Scholar
• SCHMID P, KIEWE P, KUEHNHARDT D et al.: A Phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors. J. Clin. Oncol. (2005) 23(16S):2051.
   Google Scholar
• LOW JA, WEDAM SB, LEE JJ et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J. Clin. Oncol. (2005) 23(12):2726-2734.
   PubMed Web of Science ®Google Scholar
• GALSKY MD, SMALL EJ, OH WK et al.: Multi-institutional randomized Phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J. Clin. Oncol. (2005) 23(7):1439-1446.
   PubMed Web of Science ®Google Scholar
• HUSSAIN M, TANGEN CM, LARA PN Jr et al.: Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J. Clin. Oncol. (2005) 23(34):8724-8729.
   PubMed Web of Science ®Google Scholar
• ENG C, KINDLER HL, NATTAM S et al.: A Phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann. Oncol. (2004) 15(6):928-932.
   PubMed Web of Science ®Google Scholar
• OKUNO S, MAPLES WJ, MAHONEY MR et al.: Evaluation of epothilone B analog in advanced soft tissue sarcoma: a Phase II study of the Phase II consortium. J. Clin. Oncol. (2005) 23(13):3069-3073.
   PubMed Web of Science ®Google Scholar
• AJANI JA, SHAH MA, BOKEMEYER C et al.: Phase II study of the novel epothilone BMS-247550 in patients (pts) with metastatic gastric adenocarcinoma previously treated with a taxane. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 619).
   PubMed Web of Science ®Google Scholar
• THOMAS E, TABERNERO J, FORNIER M et al.: A Phase II study of the epothilone B analog BMS-247550 in patients (pts) with taxane-resistant metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 30).
   PubMed Web of Science ®Google Scholar
• ROCHE HH, CURE H, BUNNELL C et al.: A Phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 69).
   Web of Science ®Google Scholar
• CHEN T, MOLINA A, MOORE S et al.: Epothilone B analog (BMS-247550) at the recommended Phase II dose (RPTD) in patients (pts) with gynecologic (gyn) and breast cancers. J. Clin. Oncol. (2004) 23(14S):2115.
   Google Scholar
• SINGH DA, KINDLER HL, ENG C et al.: Phase II trial of the epothilone B analog BMS-247550 in patients with hepatobiliary cancer. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1127).
   Web of Science ®Google Scholar
• VAN STEENKISTE JF, BRETON J-L, SANDLER A et al.: A randomized Phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 2519).
   PubMed Web of Science ®Google Scholar
• WHITEHEAD RP, McCOY SA, RIVKIN SE, GROSS HM, CONRAD ME, ABBRUZZESE JL: A Phase II trial of epothilone B analogue BMS-247550 (NSC 710428) in patients with advanced pancreas cancer: a Southwest Oncology Group Study. J. Clin. Oncol. (2004) 23(14S):4012.
   Google Scholar
• FOJO AT, MENEFEE ME, PORUCHYNSKY M et al.: A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): assessment of its activity and demonstration of target engagement in tumor cells. J. Clin. Oncol. (2005) 23(16S):4541.
   Web of Science ®Google Scholar
• PAVLICK AC, MILLWARD M, FARRELL K et al.: A Phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC710428) in stage IV malignant melanoma (MM). J. Clin. Oncol. (2004) 23(14S):7542.
   Google Scholar
• SMITH SM, PRO B, VAN BESIEN K et al.: A Phase II study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin’s lymphomas. J. Clin. Oncol. (2005) 23(16S):6625.
   Web of Science ®Google Scholar
• O’CONNOR O, STRAUS D, MOSKOWITZ C et al.: Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone anlog BMS 247550 induces major and durable remissions in very drug resistant disease. J. Clin. Oncol. (2005) 23(16S):6569.
   PubMed Web of Science ®Google Scholar
• HUSSAIN A, DIPAOLA RS, BARON AD et al.: A Phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC). J. Clin. Oncol. (2004) 23(14S):4563.
   Google Scholar
• POPLIN E, MOORE M, O’DWYER P et al.: Safety and efficacy of EPO906 in patients with advanced colorectal cancer: a review of 2 Phase II trials. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1135).
   Web of Science ®Google Scholar
• ANTHONY LB, CARLISLE T, POMMIER R, BENSON A, RAFFERTY T, ROTHERMEL J: An open-label Phase IIA trial evaluating the safety and efficacy of EPO906 as therapy in patients with metastatic carcinoid and other neuroendocrine tumors. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1413).
   Google Scholar
• KAYE S, OZA A, GORE M et al.: Preliminary results from a Phase II trial of EPO906 in patients with advanced refractory ovarian cancer. Eur. J. Cancer (2002) 38(Suppl. 7):S43.
   Web of Science ®Google Scholar
• THOMPSON JA, SWERDLOFF J, ESCUDIER B et al.: Phase II trial evaluating the safety and efficacy of EPO906 in patients with advanced renal cancer. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1628).
   Google Scholar
• SMIT WM, SUFLIARISKY J, SPANIK S et al.: Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer. J. Clin. Oncol. (2005) 23(16S):5056.
   Google Scholar
• YEE L, LYNCH T, VILLALONA-CALERO M et al.: A Phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer. J. Clin. Oncol. (2005) 23(16S):7127.
   Google Scholar
• OVERMOYER B, WAINTRAUB S, KAUFMAN PA et al.: Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. J. Clin. Oncol. (2005) 23(16S):778.
   Google Scholar
• SAWAKI M, ITO Y, HASHIMOTO D et al.: Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study. Tumori (2004) 90(1):36-39.
   PubMed Web of Science ®Google Scholar
• TAGUCHI T, AIHARA T, TAKATSUKA Y et al.: Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan. Breast J. (2004) 10(6):509-513.
   PubMedGoogle Scholar
• VALERO V, JONES SE, VON HOFF DD et al.: A Phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J. Clin. Oncol. (1998) 16(10):3362-3368.
   PubMed Web of Science ®Google Scholar
• FUMOLEAU P, LARGILLIER R, CLIPPE C et al.: Multicentre, Phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur. J. Cancer (2004) 40(4):536-542.
   PubMed Web of Science ®Google Scholar
• REICHARDT P, VON MINCKWITZ G, THUSS-PATIENCE PC et al.: Multicenter Phase II study of oral capecitabine (Xeloda™) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann. Oncol. (2003) 14(8):1227-1233.
   PubMed Web of Science ®Google Scholar
• WIST EA, SOMMER HH, OSTENSTAD B et al.: Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol. (2004) 43(2):186-189.
   PubMed Web of Science ®Google Scholar
• MILLER KD, CHAP LI, HOLMES FA et al.: Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. (2005) 23(4):792-799.
   PubMed Web of Science ®Google Scholar
• RHA SY, MOON YH, JEUNG HC et al.: Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res. Treat. (2005) 90(3):215-221.
   PubMed Web of Science ®Google Scholar
• MODI S, CURRIE VE, SEIDMAN AD et al.: A Phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin. Breast Cancer (2005) 6(1):55-60.
   PubMed Web of Science ®Google Scholar
• SCHUETTE W, NAGEL S, BLANKENBURG T et al.: Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J. Clin. Oncol. (2005) 23(33):8389-8395.
   PubMed Web of Science ®Google Scholar
• PECTASIDES D, PECTASIDES M, FARMAKIS D et al.: Comparison of docetaxel and docetaxel–irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized Phase II trial. Ann. Oncol. (2005) 16(2):294-299.
   PubMedGoogle Scholar
• HANNA N, SHEPHERD FA, FOSSELLA FV et al.: Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. (2004) 22(9):1589-1597.
   PubMed Web of Science ®Google Scholar
• TANNOCK IF, DE WIT R, BERRY WR et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. (2004) 351(15):1502-1512.
   PubMed Web of Science ®Google Scholar
• ROSENBERG JE, KELLY WK, MICHAELSON MD et al.: A randomized Phase II study of ixabepilone (Ix) or mitoxantrone and prednisone (MP) in patients with taxane (T)-resistant hormone refractory prostate cancer (HRPC). J. Clin. Oncol. (2005) 23(16S):4566.
   Google Scholar
• LARKIN JM, GORE ME: The MRC randomised-controlled trial of interferon-α, interleukin-2 and 5-fluorouracil versus interferon-α alone in patients with advanced renal cell carcinoma (RE04): rationale and progress. Clin. Oncol. (R. Coll. Radiol.) (2005) 17(5):319-321.
   PubMed Web of Science ®Google Scholar
• EINZIG AI, GOROWSKI E, SASLOFF J, WIERNIK PH: Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest. (1991) 9(2):133-136.
   PubMed Web of Science ®Google Scholar
• BRUNTSCH U, HEINRICH B, KAYE SB et al.: Docetaxel (Taxotere™) in advanced renal cell cancer. A Phase II trial of the EORTC Early Clinical Trials Group. Eur. J. Cancer (1994) 30A(8):1064-1067.
   PubMed Web of Science ®Google Scholar
• MERTENS WC, EISENHAUER EA, JOLIVET J et al.: Docetaxel in advanced renal carcinoma. A Phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. (1994) 5(2):185-187.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, MICHAELSON M, REDMAN BG et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(1):16-24.
   PubMed Web of Science ®Google Scholar
• AHMAD T, EISEN T: Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin. Cancer Res. (2004) 10(18 Part 2):6388S-6392S.
   PubMed Web of Science ®Google Scholar
• ATKINS M, REGAN M, McDERMOTT D et al.: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. (2005) 11(10):3714-3721.
   PubMed Web of Science ®Google Scholar